Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 16/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474826 | 0.88 | EPHX2 (0.76) | RXFP1ALDH1A1EPHX2CYP2C9 | |
| SCHEMBL12383714 | 0.80 | EPHX2 (0.82) | EPHX2CYP2C9 | |
| SCHEMBL12385395 | 0.79 | EPHX2 (0.80) | EPHX2CYP2C9KDM4E | |
| SCHEMBL12383746 | 0.79 | EPHX2 (0.80) | EPHX2CYP2C9KDM4E | |
| SCHEMBL12385462 | 0.79 | EPHX2 (0.71) | EPHX2CYP2C9KDM4E | |
| SCHEMBL12385715 | 0.78 | EPHX2 (0.66) | EPHX2CYP2C9KDM4E | |
| SCHEMBL12385590 | 0.77 | EPHX2 (0.64) | RXFP1ALDH1A1EPHX2CYP2C9KDM4E | |
| SCHEMBL12385582 | 0.77 | EPHX2 (0.69) | EPHX2CYP2C9KDM4E | |
| SCHEMBL12383112 | 0.77 | EPHX2 (0.69) | EPHX2CYP2C9KDM4E | |
| SCHEMBL12383115 | 0.77 | EPHX2 (0.64) | EPHX2CYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, PCSK9 | RXFP1 2691/4885ALDH1A1 445/4885EPHX2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.